Dermapharm Holding SE engages in the development, manufacture and market of patent-free pharmaceutical products. The firm operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. The company holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The firm offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. The company is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Hasılat
1,168
305
295
294
272
302
Hasılat Artışı (YoY)
-1%
1%
2%
-5%
-3%
1%
Satınalma Maliyeti
376
98
91
99
88
103
Brüt Kâr
791
207
203
195
184
199
Satış, Genel ve İdari
294
78
73
67
75
75
Araştırma ve Geliştirme
--
--
--
--
--
--
İşletme Giderleri
559
137
152
130
139
139
Diğer Finansman Gelirleri (Giderleri)
0
0
--
--
0
0
Kâr Öncesi Gelir
195
61
46
55
32
49
Kira Vergisi Gideri
52
16
10
14
11
16
Net Kâr
144
45
36
41
20
33
Net Income Growth
Kâr Artışı
40%
36%
80%
28%
18%
-23%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
53.81
53.81
53.45
54.38
53.57
53.87
Hisse Değişimi (Yıllık Üst Üste)
0%
0%
0%
1%
0%
0%
EPS (Diluted)
2.67
0.84
0.69
0.75
0.39
0.62
EPS Artışı
39%
35%
80%
27%
22%
-23%
Öz sermaye akışı
240
47
82
54
55
-5
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
67.72%
67.86%
68.81%
66.32%
67.64%
65.89%
Faaliyet Kâr Marjı
19.77%
22.95%
17.28%
21.76%
16.17%
19.53%
Kâr Marjı
12.32%
14.75%
12.2%
13.94%
7.35%
10.92%
Özsermaye Karlılık Oranı
20.54%
15.4%
27.79%
18.36%
20.22%
-1.65%
EBITDA
323
90
82
85
64
78
EBITDA Marjinali
27.65%
29.5%
27.79%
28.91%
23.52%
25.82%
D&A EBITDA için
92
20
31
21
20
19
Faaliyet Kârı
231
70
51
64
44
59
Faaliyet Kâr Marjı
19.77%
22.95%
17.28%
21.76%
16.17%
19.53%
Verilen Vergi Oranı
26.66%
26.22%
21.73%
25.45%
34.37%
32.65%
Follow-Up Questions
Quels sont les états financiers clés de Dermapharm Holding SE ?
Selon le dernier état financier (Form-10K), Dermapharm Holding SE a un total d'actifs de $0, un bénéfice net kayıp de $0
Quels sont les ratios financiers clés pour DMPHF ?
Le ratio de liquidité de Dermapharm Holding SE est 0, la marge nette est 0, les ventes par action sont de $0.
Comment les revenus de Dermapharm Holding SE sont-ils répartis par segment ou géographie ?
Dermapharm Holding SE en büyük gelir kaynağı Branded Pharmaceuticals olup, en son kar bildiriminde geliri 617,158,000 dir. Coğrafi olarak, Germany , Dermapharm Holding SE için ana pazar olup, geliri 696,402,000 dir.
Dermapharm Holding SE est-elle rentable ?
hayır, selon les derniers états financiers, Dermapharm Holding SE a un bénéfice net kayıp de $0
Dermapharm Holding SE a-t-elle des passifs ?
hayır, Dermapharm Holding SE a un passif de 0
Combien d'actions en circulation Dermapharm Holding SE a-t-elle ?
Dermapharm Holding SE a un total d'actions en circulation de 0